Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Noopept
GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester
A synthetic dipeptide-derived nootropic developed in Russia, structurally related to the racetam family but approximately 1000x more potent by weight. Approved as a prescription drug in Russia for cognitive impairment.
A synthetic heptapeptide analog of tuftsin developed by the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Widely used for anxiety reduction and cognitive enhancement without sedation.
Modulates AMPA and NMDA glutamate receptors, enhancing long-term potentiation (LTP) — the cellular basis of learning and memory. Increases BDNF and NGF expression in the hippocampus. Also has anxiolytic properties via modulation of inhibitory neurotransmission.
Modulates GABA-A receptor activity and increases BDNF expression. Stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic breakdown, prolonging their anxiolytic effects. Also modulates serotonin, dopamine, and norepinephrine systems.
- Cognitive enhancement
- Memory improvement
- Neuroprotection
- Anxiety reduction
- Post-concussion recovery
- Anxiety and stress reduction
- Cognitive enhancement and focus
- Depression support
- Immune system modulation
- Memory improvement
- Headache (most common)
- Irritability at high doses
- Insomnia if taken late in day
- Limited Western clinical data
- Long-term safety unknown
- Limited Western clinical trial data
- Nasal spray may cause mild irritation
- Potential fatigue at higher doses
- Long-term safety profile not established in Western populations
- Interactions with other anxiolytics not well characterized
No FDA regulatory category. Available as a research chemical in the US. Approved as a prescription drug in Russia. Not a dietary supplement under US law.
Not FDA-approved and not currently on any FDA compounding list. Available as a research chemical. Approved in Russia as an anxiolytic drug. Not affected by the April 2026 Category 2 removal action.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.